We are an integrated biopharmaceutical company at the forefront of global biotechnological innovation, dedicated to addressing significant unmet medical needs. We have built world-leading research and development capabilities in innovative large-molecule oncology therapies, including antibody-drug conjugates (ADCs), guidance, navigation & control (GNC) multi-specific antibodies, and antibody-radionuclide conjugates (ARCs), together with global clinical development expertise, and commercial-scale, cost-efficient manufacturing and supply capacity, and we aim to establish full global commercialization capabilities by 2029.
Focus on the oncology field and concentrate on cutting-edge innovations in global biotechnology
Upholding our growth strategy of “combining the advantages of North America’s 0-to-1 innovation ecosystem with China’s 1-to-N innovative scale-ups, building unique core competitiveness, and becoming a multinational pharmaceutical company (MNC),” we are steadfast in our commitment to become an MNC that continuously maintains a global leadership in oncology.
From 2015 to 2023, the company was listed among the "Top 20 Chinese Pharmaceutical Enterprises with the Best R&D Product Pipeline" for nine consecutive years. It was also named one of the "Top 20 Innovative Pharmaceutical Companies" from 2015 to 2022.
The company is recognized as a National High-Tech Enterprise, a National Intellectual Property Demonstration Enterprise, and a Sichuan Province Technology Innovation Demonstration Enterprise.
It operates a National Enterprise Technology Center and a National Postdoctoral Research Workstation.
Sichuan Province "Specialized, Refined, Distinctive, and Innovative" Small and Medium-sized Enterprise
